Eli Lilly (LLY)

934.60
+83.39 (9.80%)
NYSE · Last Trade: Apr 30th, 10:45 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close851.21
Open898.78
Bid932.48
Ask933.00
Day's Range896.80 - 945.50
52 Week Range623.78 - 1,133.95
Volume8,236,718
Market Cap894.02B
PE Ratio (TTM)40.72
EPS (TTM)22.9
Dividend & Yield6.920 (0.74%)
1 Month Average Volume3,208,843

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · April 30, 2026
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · April 30, 2026
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Via Chartmill · April 30, 2026
Eli Lilly (LLY) Q1 2026 Earnings Transcriptfool.com
Eli Lilly (LLY) Q1 2026 Earnings Transcript
Via The Motley Fool · April 30, 2026
Eli Lilly (NYSE:LLY) Shatters Q1 Expectations with Blowout Earnings Beatchartmill.com
Via Chartmill · April 30, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · April 30, 2026
Why Eli Lilly Stock Just Poppedfool.com
GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer.
Via The Motley Fool · April 30, 2026
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demandbenzinga.com
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.
Via Benzinga · April 30, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 30, 2026
Eli Lilly Obliterates Sales Forecasts By $2 Billion, Shares Surgeinvestors.com
Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance.
Via Investor's Business Daily · April 30, 2026
Discover the top S&P500 movers in Thursday's pre-market session.chartmill.com
Via Chartmill · April 30, 2026
Eli Lilly (NYSE:LLY) Delivers Strong Q1 CY2026 Numbers, Stock Soars
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ...
Via StockStory · April 30, 2026
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.fool.com
The biotech's candidate may treat a great number of illnesses that have one thing in common.
Via The Motley Fool · April 30, 2026
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analystsbenzinga.com
Eli Lilly & Co. (LLY) will release Q1 earnings on April 30. Analysts expect $6.79/share, up from $3.34/share last year. LLY down 2.6% on Wed.
Via Benzinga · April 30, 2026
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 29, 2026
Eli Lilly (LLY) Q1 Earnings: What To Expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Thursday before market hours. Here’s what to expect. Eli Lilly beat analyst...
Via StockStory · April 28, 2026
Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks Sofool.com
And he may be right.
Via The Motley Fool · April 28, 2026
Why WeightWatchers (WW) Shares Are Trading Lower Today
What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) fell 5.3% in the afternoon session after the company announced its intention to...
Via StockStory · April 28, 2026
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Meansmarketbeat.com
Via MarketBeat · April 28, 2026
Is This Deal a Game Changer for Novo Nordisk?fool.com
The drugmaker is getting on the AI train in ways that could move the needle down the road.
Via The Motley Fool · April 27, 2026
Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lillyfool.com
Eli Lilly has more to offer than some investors realize.
Via The Motley Fool · April 27, 2026
Should You Buy HIMS Stock Following Friday's Rally?
Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.
Via Barchart.com · April 27, 2026
Should You Buy the Dip in Eli Lilly Stock Today?
Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.
Via Barchart.com · April 27, 2026
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 27, 2026
Is Bristol Myers Squibb the Best Bargain in Big Pharma?fool.com
This pharma stock is cheap for a reason.
Via The Motley Fool · April 27, 2026